• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of plosgenPLoS GeneticsSubmit to PLoSGet E-mail AlertsContact UsPublic Library of Science (PLoS)View this Article
PLoS Genet. Oct 2007; 3(10): e177.
Published online Oct 19, 2007. doi:  10.1371/journal.pgen.0030177
PMCID: PMC2041992

Genome-Wide Screen for Modifiers of Ataxin-3 Neurodegeneration in Drosophila

Harry Orr, Editor

Abstract

Spinocerebellar ataxia type-3 (SCA3) is among the most common dominantly inherited ataxias, and is one of nine devastating human neurodegenerative diseases caused by the expansion of a CAG repeat encoding glutamine within the gene. The polyglutamine domain confers toxicity on the protein Ataxin-3 leading to neuronal dysfunction and loss. Although modifiers of polyglutamine toxicity have been identified, little is known concerning how the modifiers function mechanistically to affect toxicity. To reveal insight into spinocerebellar ataxia type-3, we performed a genetic screen in Drosophila with pathogenic Ataxin-3-induced neurodegeneration and identified 25 modifiers defining 18 genes. Despite a variety of predicted molecular activities, biological analysis indicated that the modifiers affected protein misfolding. Detailed mechanistic studies revealed that some modifiers affected protein accumulation in a manner dependent on the proteasome, whereas others affected autophagy. Select modifiers of Ataxin-3 also affected tau, revealing common pathways between degeneration due to distinct human neurotoxic proteins. These findings provide new insight into molecular pathways of polyQ toxicity, defining novel targets for promoting neuronal survival in human neurodegenerative disease.

Author Summary

Spinocerebellar ataxia type-3 is the most common dominantly inherited movement disorder and is caused by a CAG repeat expansion within the gene ATXN3, encoding the Ataxin-3 protein. This leads to a protein with an expanded polyglutamine domain, which confers a dominant toxicity on the protein, leading to late onset, progressive neural degeneration in the brain. Although some modifiers of Ataxin-3 toxicity have been defined, little was known about their molecular mechanisms of action. The fruit fly Drosophila recapitulates fundamental aspects of the human disease. Here, we performed a genome-wide screen for new modifiers of Ataxin-3 toxicity using the fly and defined 25 modifiers in 18 genes. The majority of the genes belong to chaperone and ubiquitin proteasome pathways, which modulate protein folding and degradation, but the remaining modifiers have a broad range of predicted molecular functions. Assays in vivo revealed that the biological activity of all modifiers converge on aiding in situations of protein misfolding, despite distinct predicted molecular functions. Select modifiers of Ataxin-3 toxicity also modulated tau toxicity associated with Alzheimer disease. These findings underscore the importance of protein homeostasis pathways to disease and provide the foundation for new therapeutic insight.

Introduction

Spinocerebellar ataxia type 3 (SCA3) is the most common dominantly inherited ataxia worldwide and is caused by a CAG repeat expansion encoding glutamine within the ATXN3 gene [1,2]. The expanded polyglutamine (polyQ) is thought to confer toxicity on the protein Ataxin-3, leading to neural dysfunction and loss [3]. At least nine human diseases, including additional spinocerebellar ataxias and Huntington's disease, share this mechanism. Studies on such pathogenic proteins reveal that the long polyQ domain alters protein conformation, causing an enriched beta sheet structure [4]. Mutant polyQ protein also dynamically associates with chaperones and colocalizes with proteasome subunits, indicating that the protein is misfolded or abnormally folded [5,6]. Such accumulation of misfolded protein is a common pathology of human degenerative disorders, including Alzheimer, Parkinson, and prion diseases [79], indicating that these diseases may share molecular and cellular mechanisms.

Models for human neurodegenerative diseases in simple systems have provided valuable tools to dissect molecular mechanisms of disease pathology [1013]. Directed expression of pathogenic human Ataxin-3 in Drosophila recapitulates key features of disease, with late-onset neuronal dysfunction and degeneration accompanied by ubiquitinated inclusions [14,15]. Neurotoxicity is more severe with increasing length of the polyQ repeat, similar to the human disease where longer repeats are associated with more severe and earlier onset disease [16,17]. In the fly, increased levels of expression of the disease protein leads to more severe degeneration and earlier onset protein accumulation, suggesting that abnormal accumulation of the mutant protein is central to disease and degeneration.

A number of modifiers of select polyQ disease proteins have been identified using animal models, including chaperones, transcriptional coregulators, and microRNAs [1822]. Although these approaches have revealed genes that modulate polyQ toxicity, little is known regarding how the modifiers act biologically to modulate polyQ degeneration. Among polyQ proteins, Ataxin-3 is unique because it has been implicated in ubiquitin pathways, and its normal activity may impinge on protein degradation pathways [2326]. Truncation of Ataxin-3 to remove the ubiquitin protease domain, or mutation of the ubiquitin protease activity, dramatically enhances toxicity [15], indicating that the normal activity of Ataxin-3 may be critical in Ataxin-3-induced degeneration. To reveal insight into pathways that modulate Ataxin-3 neurodegeneration, we performed a genetic modifier screen in Drosophila. These studies revealed a range of modifiers that, despite some broadly diverse predicted molecular functions, converge on protein misfolding with a subset mitigating toxicity through proteasome and/or autophagy pathways. These findings underscore the critical role of protein quality control in SCA3 pathogenesis and provide potential new targets toward therapeutics.

Results

A Genetic Screen Defines Modifiers of Pathogenic Ataxin-3 Toxicity

To define modifiers that may reveal new insight into mechanisms of human SCA3 disease, we performed an overexpression screen for modifiers of Ataxin-3-induced neurodegeneration in Drosophila. SCA3trQ78 causes late onset progressive degeneration characterized by loss of pigmentation and collapse of the eye (Figure 1A and and1B)1B) [14]. We initially screened a subset of 2,300 available EP-element insertion lines, each carrying a transposon engineered to direct expression of the downstream gene in the presence of the yeast GAL4 protein [27]. Because reproducibility was variable with this collection, we then performed a screen de novo, selecting for new EP-insertions that modified SCA3trQ78 toxicity. This approach identified 17 suppressors and one enhancer (Figures 1C–1J and S1), which affected both external and internal retinal degeneration.

Figure 1
Modifiers of SCA3trQ78-Induced Neurodegeneration in Drosophila Eye and Internal Retinal Sections of 1-d Flies

Plasmid rescue was performed to identify the genes affected. BLAST searches with genomic sequence from the integration sites revealed that the lines bore insertions in the 5′ regulatory region of select genes, and all were in an orientation to direct GAL4-dependent gene expression (Text S1; Table S1). Northern and reverse transcription PCR analysis confirmed upregulation of the targeted genes; using a variety of tests we confirmed that the modifiers did not appear to affect transcription of the Ataxin-3 transgene or general GAL4-UAS transgene expression (Figure S2). Both molecular and genetic analyses confirmed that the insertions were single insertions (see Materials and Methods). Reversion analysis proved that the EP-elements were causal in modification. Taken together, these data indicated that the EP modifiers resulted in increased expression of the targeted downstream genes, which modulated SCA3trQ78 toxicity and neurodegeneration.

Molecular Analysis Implicates Diverse Biological Pathways

Analysis of the targeted genes revealed that the majority fell into two major classes of chaperones and ubiquitin-pathway components (Table 1; Figures S1 and S3). The remaining modifiers were placed in a third category of miscellaneous functions. Class 1 (Figure 1C–1E) included an Hsp70 family member, Hsp68E407; two Hsp40 genes, DnaJ-1B345.2 and mrjE1050; a small heat shock protein αB crystalline CG14207EP1348; and the cochaperone Tpr2EB7-1A. The class 2 ubiquitin-pathway components included: polyubiquitin CR11700EP1384; a ubiquitin-specific protease Ubp64EE213-1A; two ubiquitin ligases, CG8209B3-Sa and Faf E659; and an F-box protein CG11033EP3093, the only enhancer of the group. Class 3 (Figure 1F and and1G)1G) included genes with a variety of predicted molecular functions: the nuclear export protein Embargoed, embE2-1A and embE128-1A; three transcriptional regulators Sin3AB9-E, NFAT (NFATEP1335 and NFATEP1508), and debra (dbrEP456 and dbrEP9); three translational regulators, including four alleles of the lin-41 homologue dappled (dpldJM120, dpldJM265, dpldEP546, and dpldEP2594), a polyA binding protein orb2B8-S, and insulin growth factor II mRNA binding protein ImpEP1433; and finally a fatty acid oxidation enzyme palmitoyl co-A oxidase CG5009B227.2. This indicated that, although chaperone and ubiquitin-pathway components are major modifier categories, a variety of functional pathways are implicated in Ataxin-3 pathogenesis.

Table 1
Activities of Genetic Modifiers of Ataxin-3 Neurodegeneration

The screen selected for modifiers that, upon upregulation, affected toxicity. To determine whether the activity of these genes may normally play a role in SCA3 toxicity, we examined whether reduction in the level of the modifier genes had an effect. To do this, we reduced gene expression by 50% using loss-of-function alleles where available or deficiency lines. Among these, reduction with a deficiency of DnaJ-1 and Ubp64E (within the same deficiency; reduction of DnaJ-1 has previously been shown to enhance with a dominant-negative construct [16]), Trp2, emb (with an allele), and dbr dramatically enhanced degeneration (Figure 1K–1O; Table S2). Although the deficiencies reduce the level of a number of genes, these data suggest that the endogenous activity of these genes may normally help to protect against degeneration.

To address whether morphological rescue correlated with functional rescue, we determined the ability of select suppressors to restore function in a phototaxis assay. When flies bearing the SCA3trQ78 protein were given a choice between a light and dark chamber, they distributed randomly, indicating that they are functionally blind (Figure 1P). However, when mrjE1050, which dramatically rescued degeneration, was co-expressed, normal vision was restored. A milder suppressor that anatomically restored less retinal tissue, CG14207EP1348, restored vision partially. Thus, anatomical rescue correlated with functional rescue. These and other studies indicated that the modifiers not only modulated toxicity of the external eye, but also that of the neuronal cells. To confirm this in another situation, we tested select modifiers for the ability to mitigate polyQ toxicity when directed exclusively to the nervous system with elav-GAL4 (Figure S4). These studies confirmed that the modifiers mitigated neuronal toxicity of the Ataxin-3 protein.

We performed select additional experiments with dpld, for which we obtained many independent EP overexpression alleles. These detailed studies confirmed activity of the EP alleles of dpld with independent UAS-dpld transgenic lines. Further, suppression by dpld was not limited to development but also extended to the adult timeframe (Figures S2, S5, and S6).

Because the genes were isolated as modifiers of a truncated Ataxin-3 protein, we tested whether they could mitigate toxicity of full-length Ataxin-3, which is largely a neuronal toxicity [15]. Modifiers that phenotypically strongly suppressed toxicity of truncated Ataxin-3 also strongly suppressed full-length Ataxin-3 toxicity; however, a number of modifiers that were weak or moderate suppressors of the truncated protein were, in contrast, strong suppressors of full-length Ataxin-3: CG14207EP1348 (αB crystalline), CR11700EP1384 (polyubiquitin), CG8209B3-Sa (putative ubiquitin ligase), and Sin3AB9-E (Figure S7 and unpublished data). Consistent with strong anatomical rescue, CG14207EP1348 also robustly suppressed functional vision defects of full-length Ataxin-3 (Figure 1Q). The enhancer, however, CG11033EP3093 had a minimal effect on toxicity of full-length Ataxin-3 (unpublished data). This indicated that the modifiers varied in strength and selectivity depending upon whether the Ataxin-3 protein was intact or truncated. As truncation may be a feature of SCA3 disease [2830], the effectiveness of modifiers against different forms of Ataxin-3 has implications for disease pathogenesis.

Ataxin-3 Modifiers Affect General Protein Misfolding

Previous studies have shown that the molecular chaperone Hsp70 is a potent suppressor of SCA3 toxicity [31]. Therefore, we considered that the class 1 modifiers may function similar to Hsp70 to help cells handle the misfolded disease protein, whereas those of class 2 likely have a role in ubiquitin-dependent pathways that process misfolded proteins. However, class 3 presented a range of potential activities. To address how the modifiers were functioning biologically, we tested whether the modifiers could affect a general protein misfolding phenotype: compromised chaperone activity with a dominant-negative form of Hsp70 (Hsp70.K71E). This situation results in an eye phenotype that resembles severe polyQ degeneration (Figure 2A and [32]). Thus, modifiers that affected both SCA3 and Hsp70.K71E toxicity would likely include those whose mode of action was to modulate protein misfolding.

Figure 2
EP Modifiers Strongly Affect General Protein Misfolding Defects

Strikingly, we found that most of the suppressors of polyQ toxicity also mitigated the Hsp70.K71E phenotype, as well as or better than directed expression of Hsp70 itself (Figure 2; Table 1). Interestingly, DnaJ-1B345.2 and Tpr2EB7-1A enhanced this phenotype; we interpreted this to indicate that these genes, which encode proteins thought to act as cochaperones of Hsp70, may compromise residual Hsp70 in the dominant-negative situation. The chaperone mrjE1050, although an Hsp40 class chaperone, acted in a manner distinct from DnaJ-1B345.2, as it suppressed rather than enhanced the Hsp70.K17E phenotype. Moreover, the enhancer of SCA3trQ78 toxicity, CG11033EP3093, suppressed the misfolding phenotype. Only one modifier did not affect this phenotype, the ubiquitin protease Ubp64EE213-1A; interestingly, normal Ataxin-3 also has ubiquitin protease activity that mitigates its own pathogenicity, and similarly, has no effect on Hsp70.K71E [15]. We considered that one mechanism by which the modifiers may mitigate the Hsp70.K71E phenotype is by upregulating Hsp70/Hsc70 chaperones; however, none of the modifiers appeared to act in this way (Figure 2K and unpublished data). These results indicated that the majority of modifiers of SCA3trQ78 toxicity appeared to function biologically by aiding in situations of compromised chaperone activity and/or protein misfolding.

Reduced Accumulation of the Pathogenic Protein Reduces Toxicity

The degree of neurodegeneration induced by pathogenic polyQ protein is typically correlated with the level of accumulation of the protein in animals in vivo. We reasoned, therefore, that the modifiers may affect protein levels. We therefore examined protein accumulation by immunohistochemistry and western analysis. Although nuclear inclusions may not be causal in disease [33], later onset, smaller nuclear inclusions are typically reflective of reduced pathogenicity of the protein in vivo. Hsp70 and Hsp40 have also been shown to increase the solubility of pathogenic polyQ protein by western blots, concomitant with reducing toxicity [16]. We therefore examined protein accumulation using rh1-GAL4 or the full-length Ataxin-3 protein—both situations that allow sensitive analysis of protein accumulation [15,22]. In these studies, we limited analysis to the strong and moderate modifiers.

Immunohistochemical analysis revealed that select modifiers had striking effects to reduce NIs. These included the class I chaperones Hsp68E407, DnaJ-1B345.2, mrjE1050, but did not include αB-crystalline CG14207EP1348 or Tpr2EB7-1A (Figure 3; Table 1). Of the class 2 ubiquitin-pathway components, polyubiquitin CR11700EP1384 and the ubiquitin protease Ubp64EE213-1A reduced NIs, but the other strong modifiers of this class did not. Of class 3 modifiers tested, all reduced NI except ImpEP1433 (Figure 3B and and3F).3F). We then analyzed solubility of the pathogenic protein by immunoblot. This approach revealed that, although the modifiers had no effect on protein levels at early time points prior to inclusion formation, all suppressors increased the level of monomeric protein over time, thus all increased the solubility properties of the pathogenic protein (Figure 3E). The effect was specific, as co-expression of a control protein (green fluorescent protein [GFP]) had no effect (unpublished data). Similarly, the enhancer reduced monomer levels (unpublished data). These findings indicate that the modifiers either affected pathogenic protein accumulation or altered the solubility properties of the toxic protein, concomitant with altering protein pathogenicity.

Figure 3
Modifiers Affect Accumulation or Solubility of Ataxin-3 Protein

Select Modifiers Are Sensitive to In Vivo Inhibition of the Proteasome

Given that many modifiers mitigated protein accumulation, we asked whether there were interactions with genes of protein degradation pathways. A key pathway thought to modulate the pathogenic polyQ toxicity is the ubiquitin-proteasomal system (UPS) [34]. We therefore tested whether suppression by modifiers that lowered protein levels was dependent upon a fully functional proteasome. Proteasome activity can be reduced by a dominant temperature-sensitive mutation in a proteasome protein subunit (DTS5) [35]. In a situation where limiting proteasome activity using this mutation had no effect on SCA3 toxicity on its own, we found that a striking number of modifiers still suppressed polyQ toxicity, thus indicating that they were not sensitive to inhibition of the proteasome by this assay; these included dpld alleles (Figure 4; Table 1). In contrast, a striking exception was the class 2 ubiquitin-pathway suppressors: all of these modifiers lost the ability to suppress upon proteasome inhibition with the DTS mutation.

Figure 4
Degradation Pathways of Ataxin-3-Induced Neurodegeneration

Pathogenic Ataxin-3 Stimulates Autophagy, with Select Modifiers Promoting and Others Preventing Autophagy

Autophagy, or lysosome-mediated protein degradation, has also been implicated in polyQ toxicity and cell survival in situations of stress [36,37]. We therefore asked whether the modifier genes had an effect on this process. First, we determined whether normal or pathogenic Ataxin-3 itself induced lysosomal accumulation reflective of autophagy, by examining the fat body tissue from larvae, a standard assay for autophagy [38]. Normally, well-fed animals show minimal lysosomal induction, whereas starved animals show a dramatic increase, reflected by the uptake of dye (Figure 4F and and4G).4G). Whereas expression of normal Ataxin-3 (SCA3Q27) had minimal effect, expression of pathogenic Ataxin-3-induced autophagy (Figure 4J). To further address the role of autophagy, we determined whether limiting the activity of autophagy genes affected SCA3 toxicity. Key genes to which RNA interference transgenic lines are available include Atg5. Whereas reduction of Atg5 activity on its own had little effect, reducing Atg5 in the presence of pathogenic SCA3 protein appeared to enhance toxicity, with increased loss of retinal integrity (Figure 4L–4N). This suggests that, normally, autophagy may mitigate toxicity of the pathogenic protein. Reduction of autophagy also enhanced aggregation of the protein by western immunoblot and enhanced cytoplasmic protein accumulation along photoreceptor axons (Figure 4O–4Q).

We then determined whether strong modifier genes also modulated autophagy. We examined two situations: (1) to determine whether strong modifier genes could induce autophagy in well-fed animals when autophagy is normally minimal; (2) to determine whether they could block autophagy under starvation, when autophagy is stimulated as a protective mechanism. We tested these as we considered that a modifier may affect Ataxin-3 pathogenicity either by inducing autophagy-mediated lysosomal degradation of the pathogenic protein, or alternatively, by blocking autophagy if autophagy contributes to loss of the cells in response to mutant polyQ protein. These studies revealed that select modifiers induced, whereas others mitigated, autophagy (Figure 4H, H,4I,4I, and and4K).4K). Of the class 1 chaperone modifiers, the two Hsp40 genes (DnaJ-1B345.2 and mrj E1050) increased autophagy, whereas Hsp70 and the class 3 modifier ImpEP1433 reduced autophagy. Although Dpld showed no effect in these assays, limiting autophagy by reduction of Atg5, Atg7, or Atg12 mitigated Dpld suppression, suggesting that its activity was dependent on autophagy (Figure 4R, R,4S,4S, and unpublished data). These and other data (Figures S8 and S9) suggested that Dpld may act upstream of autophagy genes to activate autophagy in select situations. We also tested available GFP protein trap lines to examine localization of modifier proteins. Although none of these lines showed GFP immunostaining, one line with a protein trap insertion in Hsc70Cb enhanced SCA3 neuronal toxicity and increased protein accumulation in the neurophil similar to autophagy genes (Figure S8G–S8K). Taken together, these studies indicated that the modifiers, despite broad molecular nature, mitigated situations of protein misfolding; in some cases their activity appeared dependent on the proteasome, whereas others may involve autophagy-based protein clearance or autophagy-related cell loss.

Select Modifiers Affect Other Pathogenic Human Disease Models

The modifiers were selected based on ability to modulate SCA3 degeneration; however, our studies suggested that the modifiers may have broader functions in protein misfolding. We therefore determined whether they could modulate toxicity of tau. Abnormal accumulation of tau in neurofibrillary tangles or mutations in tau are associated with Alzheimer disease and frontotemporal dementia [39]. Tau-induced degeneration is mitigated by the caspase inhibitor P35 and DIAPs, implicating programmed cell death pathways in tau toxicity [40]. Expression of normal (tau.wt) or mutant (tau.R406) tau causes toxicity reflected in a reduced and degenerate eye [41]. Co-expression of the class 1 chaperone Tpr2EB7-1A and the Hsc70Cb line class 2 modifier polyubiquitin CR11700EP1384, and class 3 modifiers dpld JM265, ImpEP1433, and CG5009B227.2 strikingly suppressed toxicity of tau (Figure 5; Figure S8). The class 3 modifier embE2-1A enhanced tau (Figure 5), whereas NFAT EP1335 enhanced tau.wt, but had no effect on mutant tau.R406W (unpublished data). We then examined the ability of the modifiers to affect programmed cell death. Several class 3 modifiers had an effect on hid-induced eye loss: co-expression of embE2-1A and NFATEP1508 enhanced hid, whereas ImpEP1433 and dpldJM265 alleles suppressed hid-induced cell death (Figure 5 and unpublished data). Alleles of those genes that modulated tau and programmed cell death similarly (emb, dpld, NFAT, and Imp) may modulate tau toxicity by altering cell death. In contrast, the others (Tpr2, polyubiquitin CR11700, and Hsc70Cb) likely modulate tau toxicity through other means. Taken together, these data indicate that select modifiers that influence cell survival and protein misfolding may be common to both SCA3 and tau-induced degeneration.

Figure 5
Select Ataxin-3 Modifiers also Modulate Tau Toxicity

Discussion

We present a detailed functional analysis of genetic modifiers of pathogenic Ataxin-3 induced neuronal toxicity. The majority of modifiers fell into chaperone and ubiquitin pathways, consistent with the proposed function of Ataxin-3 in the ubiquitin-proteasome pathway, as well as pathways implicated in polyQ toxicity. Strikingly, however, biological assays for the activity of modifiers, some of which are predicted to function in diverse biological processes, indicated that their activities also converge on protein misfolding. Several protein quality control pathways appear involved, including the UPS and autophagy. These findings underscore the significance of protein quality control pathways to SCA3 and potentially other age-dependent protein conformation diseases.

A Genetic Screen for Modifiers That Mitigate PolyQ Degeneration

Our screen was designed to identify upregulation modifiers, targeting genes whose increased activity could modulate neuronal toxicity and degeneration of a pathogenic Ataxin-3 protein. This screen identified activities that may become compromised or normally insufficient in the disease protein situation. A number of modifiers appeared dosage sensitive, in that reduction of the genetic region encoding the gene enhanced degeneration. This suggests that, at least for select modifiers, their normal activity is also critical for maintenance of neurons in disease.

Because of the severity of the degenerate eye, we may have selected for particularly strong modifiers. Modifiers were also initially selected for the ability to mitigate an external eye degeneration, rather than direct neuronal toxicity. Despite this, all of the modifiers mitigated internal neural degeneration. This indicates that the degree of external eye degeneration is a reasonable predictor of internal neuronal integrity. A number of modifiers were identified multiple times (dpld, NFAT, emb, and dbr), although most were found only once, indicating that the screen is not saturated. Additional screens using different mutagens or different types of screening approaches may reveal additional and different classes of modifiers. Although the modifiers were selected for mitigation of toxicity of a truncated Ataxin-3 protein, nearly all effectively mitigated toxicity of the full-length pathogenic protein. Our previous and other studies suggest that truncation may normally occur in disease to remove the N-terminal ubiquitin protease domain and would dramatically enhance degeneration [15,29,30]. Therefore, these are efficacious modifiers that mitigate toxicity of various forms of the pathogenic protein.

Chaperones and Ubiquitin-Pathway Components Are Critical Regulators of SCA3

The majority of modifiers were either chaperones or, by sequence and functional tests, modulated ubiquitin-mediated protein quality control pathways. Whereas those that have sequence implications in this pathway might be anticipated, a surprise was that many genes with widely divergent molecular activities were functionally implicated in this process. These data suggest that many genes can modulate situations of protein misfolding, and moreover, suggest that protein misfolding is central to polyQ pathogenesis. It is also possible that, given the normal function of Ataxin-3 in ubiquitin-modulated pathways, the screen selected for modifiers that impinge on normal activities of Ataxin-3. Among the modifiers, some decreased protein accumulation, whereas others suppressed with no apparent change in Ataxin-3 inclusions. Of those that decreased Ataxin-3 accumulation, some appeared dependent on functional proteasome activity, whereas others stimulated autophagy, or both, implicating various mechanisms that attenuate Ataxin-3 degeneration. Among the modifiers was polyubiquitin, arguing that the level of ubiquitin itself may normally be insufficient to handle the misfolded protein over prolonged periods. This is consistent with the lack of a robust stress response to pathogenic polyQ [42]. In a Caenorhabditis elegans of model of polyQ, Gidalevitz et al. [43] reveal that polyQ expansions can cause temperature-sensitive alleles of various unrelated genes (paramyosin, dynamin, and ras) to display the mutant effect at what would normally be permissive conditions. This finding suggests that long polyQ runs can cause a general disruption of the cellular protein-folding environment to affect the temperature-sensitive mutant proteins. Our work used a pathogenic human disease protein Ataxin-3 and revealed that many modifiers that mitigate Ataxin-3 toxicity also modulate general protein misfolding. Taken together, these results suggest that, in the absence of upregulation of the various components needed, the cell may become overwhelmed, triggering deleterious effects [32]. Our detailed analysis of modifiers of Ataxin-3 have revealed a variety of biological processes that can help manage pathogenic polyQ protein, as well as specific genes of interest (Figure 6A).

Figure 6
Activities of Modifier Genes of Ataxin-3-Associated Neurodegeneration

The precise molecular pathways by which those modifiers that are not clearly within protein folding pathways can modulate misfolding to affect neurodegeneration requires further study. We envisage, however, that they function by their predicted molecular mechanisms, but on targets that impinge on cellular protein homeostasis. For example, chromatin modifiers may tweak the expression of a variety of genes in such processes, whereas translational regulators may translationally modify such genes. The finding that a variety of cellular functions are involved would be consistent with RNA interference screens in C. elegans that identified a variety of genes that impinge on cellular protein homeostasis as enhancers of the aggregation of polyQ protein [20]. These findings, along with other studies including those we present here, underscore the critical importance of proper protein homeostasis to most—if not all—cellular functions, such that a variety of genes can influence this process.

Among our modifiers, some that might have been expected to act in a similar manner, appeared to have distinct biological effects. The class 2 modifiers showed complete dependence on proper proteasome activity, while other modifiers, including alleles of DnaJ-1 and Imp, appeared to be insensitive to limiting proteasome activity, but rather affected autophagy in stress conditions. Hsp70 suppresses multiple stress conditions including protein misfolding, starvation-induced autophagy, and paraquat-induced oxidative stress [11], suggesting it may both facilitate UPS activity, but also block autophagy-dependent degeneration. In vivo, these pathways interplay to maintain proper neuronal function in the face of disease, thus further study of the modifiers may allow greater molecular identification of the individual pathways, as well as their integration.

Although only select modifiers affected protein accumulation as assayed by immunohistochemistry, all affected the solubility of the disease protein by biochemical analysis. The relationship between protein inclusions and proposed toxic oligomers is still under investigation, but it seems reasonable to suggest that the change in solubility may reflect activity of the modifiers to buffer or alter toxic conformations of the protein. Our efforts to detect toxic oligomers of Ataxin-3 using available antibodies [33,44,45] are still in progress. We note that, despite gross similarity, SCA3 degeneration is not identical to general misfolding: some suppressors of Ataxin-3 toxicity strikingly enhanced dominant-negative Hsp70 (upregulation of DnaJ-1 and Tpr2), whereas the enhancer CG11033E3093 suppressed it.

The UPS and autophagy pathways function in either degeneration or polyQ protein pathogenicity [46]. Our findings indicate that these pathways at least in part function in the removal or decrease of the toxic protein, thereby reducing degeneration. It is also possible that activities of these pathways may be inhibited during pathogenesis; such inhibition of normal activity would contribute to disease pathology [4749]. The normal function of Ataxin-3 is in ubiquitin-modulated pathways [2326]; our data suggest the possibility that Ataxin-3 may also modulate autophagy. Normal physiological levels of autophagy are critical to integrity of neurons, as loss of autophagy causes degeneration associated with ubiquitinated inclusions [50,51]. Our studies also reveal that compromise of autophagy pathways strikingly increased cytoplasmic Ataxin-3 accumulations in the neurophil without an obvious change in NIs. This may indicate that autophagy normally modulates cytoplasmic accumulation of the disease protein. Previous studies show that cytoplasmic polyQ protein is very toxic and blocks axonal transport [52]. These findings suggest that perturbations in autophagy may enhance cytoplasmic toxicity further.

In addition to regulation of the disease protein level and misfolding, results with select modifiers (Hsp70 and Imp) suggest that autophagy may also regulate loss of the cells. Given that our previous findings failed to reveal a clear role of caspase-dependent cell death in SCA3 [22], autophagy may be a mechanism of cell loss in this situation. Identification of other components of UPS and autophagy pathway will give further insights into how the disease protein is degraded and mechanisms of neuronal loss.

Relationship to Other Modifier Pathways and Screens

Genetic screens have been performed for modifiers of Ataxin-1 [19] and of pure polyQ domains [18], revealing similar components of protein folding and degradation: DnaJ-1 [18,19] and Tpr2 [18], but also RNA binding proteins and transcription factors. Although components of ubiquitin pathways that modulate Ataxin-1 appear distinct from Ataxin-3, this may reflect different regulators required for modifying different proteins or lack of saturation of the screens. Similarly several RNA binding proteins identified as modifiers of Ataxin-1 were suggested to reflect Ataxin-1 function as a putative RNA binding protein; our data suggest that it is also possible that these modifiers work more fundamentally to modulate protein solubility or levels. Our other work, however, has revealed a role for microRNAs in modulating neuronal survival in neurodegenerative situations [22,53], which has recently been extended to vertebrate neuronal integrity as well [54]. A C. elegans screen revealed a large number of modifiers of a pure polyQ aggregation phenotype [20]. Several modifiers identified in that screen affect RNA synthesis, processing, and protein synthesis as modifiers of misfolding. It will be important to test these modifiers against various specific disease proteins, as the action of a pure polyQ repeat may be distinct from a pathogenic repeat within a host protein.

One reason for global commonality among modifiers of polyQ disease proteins may be that the proteins themselves fall within a common interacting protein network. Recent studies using the yeast two-hybrid approach and proteomic databases reveal a protein interaction network of the ataxia proteins [55]. A surprise was that many different ataxia proteins, including Ataxin-3, fall within a few interaction steps from one another, suggesting that their common phenotypes may be a reflection of common interactions, which, when perturbed, contribute to disease. In that study [55], seven proteins were identified as direct interaction partners of Ataxin-3; however none of these appeared in our screen. Another direct binding protein–VCP [56]—was also not identified. However, the human orthologues of the majority of the genetic modifiers we defined fit into the protein interaction network at various points; some are direct interactors of other ataxia disease proteins, and others are one or more steps removed (Table S3).

Alzheimer disease and polyQ diseases are two unrelated human neurodegenerative diseases that cause neuronal degeneration in distinct brain regions [1,2,57]. Therefore, no overlap was expected between modifiers of these disease proteins in flies; indeed previous studies suggest minimal overlapping genes [58]. Surprisingly, we found that select modifiers of Ataxin-3 suppressed tau-degeneration, including the cochaperone Tpr2 and polyubiquitin (Figure 6B). This finding is consistent with cell culture studies and C. elegans RNA interference screens that implicate chaperones as modifiers of tau degeneration [59,60]. Further study of these modifiers, especially those that may be in common among different disease proteins, should provide the foundation for new therapeutic insight.

Materials and Methods

Drosophila stocks and crosses.

Fly lines were grown in standard cornmeal molasses agar with dry yeast at 25 °C. Transgenic lines UAS-SCA3trQ78, UAS-SCAtrQ61, UAS-SCA3Q78, and UAS-SCA3Q84 are described [1416]. General stock lines, deficiency lines, and specific alleles of the EP modifiers were obtained from the Bloomington Drosophila stock center. The emb mutant lines were from C. Samakovlis (Wenner-Gren Institute Stockholm University, Stockholm, Sweden) [61]. rh1-GAL4, gmr-hid, UAS-DTS5, autophagy inverted repeat lines (UAS-Atg5_IR and UAS-Atg7_IR), tau transgenic lines (UAS-htau and UAS-htau.R406W), UAS-brat, and Hsc70C protein trap line were kindly provided by C. Desplan (New York University, New York, New York, United States), H. Steller (Rockefeller University, New York, New York, US), J.M. Belote (Syracuse University, Syracuse, New York, US), T. Neufeld (University of Minnesota, Minneapolis, Minnesota, US), M. Feany (Harvard Medical School, Boston, Massachusetts, US), R. Wharton (Duke University Medical Center, Durham, North Carolina, US), M. Buszczakl (Johns Hopkins University, Baltimore, Maryland, US), respectively. The dominant-negative Hsp70 line is described [32]. UAS-dpld FLAG, untagged, and gfp fusion lines were generated from cDNA clone LD02463 by subcloning into the pUAST vector [62]. Excision lines for reversion were made by crossing the EP insertions to lines bearing transposase, then screening for loss of the EP element.

For the genetic screen, virgin females of the starter line EP55, bearing an EP insertion on the X chromosome [27], was crossed to males with transposase. Males were selected and crossed to virgin females that expressed the disease gene (w/w; gmr-GAL4 UAS-SCA3trQ78 Tft/CyO). F1 progeny were screened for males with either suppressed or enhanced eye phenotypes as compared to controls; any modifiers were then outcrossed and balanced. EP insertions were confirmed to be single insertions through outcrossing, as well as plasmid rescue.

Histochemistry.

Epon sections, paraffin sections, and cryosections of adult heads were performed as described [14,16]. Primary antibodies for immunostaining were anti-HA primary antibody (Y-11, 1:50, Santa Cruz Biotechnology; and 12CA5, 1:100, Roche), anti-Myc (9E10, 1:100, Santa Cruz Biotechnology), anti-Hsp70 (7FB, 1:1,000,) [63], and anti-Gfp (A6455, 1:50, Molecular Probes). Secondary antibodies included anti-mouse or anti-rabbit conjugated to Alexa Fluor 594 or 488 (1:200 or 1:100, Molecular Probes). Western immunoblots were performed as described [16]. Primary antibodies used were HA-HRP (3F10, 1:500, Roche), rat anti-Hsp70 (7FB, 1:2,000), and mouse anti-tubulin (E7, 1:2,000, Developmental Studies Hybridoma Bank), with the secondary goat anti-rat IgG (1:2,000, Roche) and goat anti-mouse IgG (1:2,000, Chemicon International).

Molecular biology.

To define the sites of EP insertion, plasmid rescue was performed [27]. To confirm single hits in the genome, multiples of clones from each EP line were sequenced with an EP 3′ P-end specific primer (5′-CAA TCA TAT CGC TGT CTC ACT CA-3′). The flanking DNA sequence was used to query flybase BLAST to define the nearby gene and exact site of insertion. Upregulation of the genes by the EP element was confirmed by northern analysis, comparing the EP line alone, to wild-type fly controls with the EP line in the presence of a GAL4 driver, using gene-specific probes generated by reverse-transcription PCR using an EP-specific primer and gene-specific primers to the target genes. That the EP insertions were single insertions was independently verified genetically by molecular and phenotypic analysis of lines.

The effect of the modifiers on transgene expression levels was examined by real-time PCR (see Text S1 and Figure S2) and by reverse-transcription PCR. For the latter, total RNA was extracted with the RNAeasy kit (74104, QIAGEN) following manufacturer's instructions. cDNA synthesis was done using SuperScript First Strand Synthesis for reverse-transcription PCR (12371–019, Invitrogen). PCR was performed using primers: for the SCA3 transcript, 5′-CTATCAGGACAGAGTTCACAT-3′ (forward) and 5′-CAGATAAAGTGTGAAGGTAGC-3′ (reverse); for the GAL4 transcript, 5′-GTCTTCTATCGAACAAGCATGCGA-3′ (forward) and 5′-TGACCTTTGTTACTACTCTCTTCC-3′ (reverse) and for rp49 control, 5′-CCAGTCGGATCGATATGCTAA-3′ (forward) and 5′-ACCGTTGGGGTTGGTGAG-3′ (reverse).

Behavioral assays.

Phototaxis was performed as described [15]. The percentage of flies in the light and dark chambers represent an average of three independent groups of flies. At least 100 flies were tested for each genotype, 20 flies were used in each experiment.

Autophagy assays.

Third instar larval fat body tissues were stained with Lyso Tracker Red DND-99 (L-7528, Molecular Probes) and Hoechst (H3570, Molecular Probes) as described [38]. For each genotype, well-fed and starved larvae were used as negative and positive controls for the assay conditions. A score of 4 was given to control larvae grown under starvation condition; autophagy for other genotypes was scored relative to this. Controls (driver line alone and/or modifier alone, in starvation and well-fed conditions) were performed for each modifier genes in parallel to the experimental situation. The final autophagy score represents the average of 20 larvae from each genotype.

Supporting Information

Figure S1

Modifiers of SCA3trQ78-Associated Neurodegeneration:

External eye and internal retinal sections of 1-d flies.

(A) Control external and internal eye. Normal retinal thickness is indicated with yellow arrow. Genotype w; gmr-GAL4/+.

(B) Expression of strong SCA3trQ78 in the eye causes external and internal degeneration with severe pigment loss and markedly reduced retinal thickness. Genotype w; gmr-GAL4 UAS-SCA3trQ78/+.

(C–T) Suppressors of SCA3tr-Q78 associated neurodegeneration in trans to w; gmr-gal4 UAS-SCA3trQ78. EP lines are (C) E407, (D) B345.2, (E) E1050, (F) EP1348, (G) EB7-1A, (H) EP1384, (I) E213-1A, (J) B3-Sa, (K) E659, (M) E2-1A, (N) B9-E, (O) EP1335, (P) EP456, (Q) JM265, (R) B8-S, (S) EP1433 and (T) B227.2. (L) EP3093 enhances SCA3trQ78-associated neurodegeneration and lethality.

(1.9 MB JPG)

Figure S2

Control Experiments for SCA3 Modifiers:

(A) (Top) Western analysis for SCA3trQ78 protein level (detected with anti-HA) in 1-d fly heads. Experiments were performed using the late onset gene expression driver rh1-GAL4. At 1 d, the pathogenic protein is soluble by immunocytochemistry and western analysis. The Ataxin-3 protein level was similar in the various situations, indicating that the modifiers do not affect expression from the GAL4-UAS system. Genotypes: w; UAS-SCA3trQ78; rh1-GAL4 in trans to + or the various EP modifier lines as indicated.

(A) (Bottom) Real-time PCR for level of transgenes shown are Tpr2EB7-1A, FafE659, Sin3AB9-E, dbrEP456, dpldJM265, orb2B8-S, ImpEP1433; CG5009B227.2 was confirmed by reverse transcription PCR (unpublished data). Genotypes: w; UAS-SCA3trQ78; rh1-GAL4 in trans to + or EP modifier lines indicated.

(B–F) Examples of modifiers that failed to affect tau toxicity. All modifiers were tested for ability to modulate the deleterious effects of a number of additional genes, including tau, hid, and others (below). Although select modifiers affected tau toxicity (either to enhance or suppress, see Figure 5), others had no effect. The inability to modulate such additional gene activities was additional evidence that the modifiers did not affect the GAL4-UAS system. Tau-induced degenerate eye is not modulated upon co-expression of EP alleles of (C) Hsp68, (D) Ubp64E, (E) CG11103, or (F) Sin3A. Genotypes: (B) w; gmr-GAL4/+; UAS-tau.R406W/+ , (C) w; gmr-GAL4/+; UAS-tau.R406W/ E407, (D) w; gmr-GAL4/+; UAS-tau.R406W/ E213-1A, (E) w; gmr-GAL4/+; UAS-tau.R406W/EP3093, and (F) w; gmr-GAL4/+; UAS-tau.R406W/ B9-E.

(G–K) Detailed analysis of controls for alleles of the dpld gene.

(G) Western analysis for SCA3trQ78 protein expression in 1-d fly heads. The EP allele of dpld (dpldJM265), generated transgenic lines of dpld (UAS-dpld, dpldJ990), and the precise excision line of the dpld JM265 allele (dpld JM265-ex) showed similar levels of disease protein at early time points compared to the control (+). This indicated that upregulation of dpld did not affect expression from the GAL4-UAS system; rather further studies showed that Dpld affected long-term accumulation of the protein (see Figure 3F and and3G).3G). Genotypes: lane 1, w; UAS-SCA3trQ78/+; rh1-GAL/+; lane 2, w; UAS-SCA3trQ78/dpld JM265; rh1-GAL4/+; lane 3, w; UAS-SCA3trQ78/+; rh1-GAL4/UAS-dpldJ990; lane 4, w; UAS-SCA3trQ78/dpld JM265-ex; rh1-GAL4/+.

(H–K) Effect of dpld expression on various deleterious GAL4/UAS-induced eye phenotypes.

(H and I) dpld expression had no effect on eyeless-induced disruption of the eye. Genotypes: (H) w; ey-GAL4 UAS-eyeless/ dpld JM265 and (I) w/+; ey-GAL4 UAS-eyeless/+.

(J and K) dpld expression did not affect the rough eye phenotype induced by expression of MAP2. Genotypes: (J) w; gmr-GAL4 UAS-MAP2/ dpld JM265 and (K) w/+; gmr-GAL4 UAS-MAP2/+.

(1.0 MB JPG)

Figure S3

Conserved Domains of Modifier Genes:

The modifiers fall into three major classes based on conserved sequence domains: genes involved in chaperone pathways, in ubiquitin pathways, and miscellaneous functions. The conserved domains for the first category include Hsp70, DnaJ, DNAJ-C, Hsp20, and tetratricopeptide repeat (TPR). The second category has ubiquitin, ubiquitin carboxy hydrolase (UCH), ubiquitin associated (UBA), ubiquitin regulatory (UBX), and F-box domains. The conserved domains for the third category include Importin-beta N terminus (IBNN), paired amphipathic helix repeat (PAH), rel homology domain (RHD), transcription factor/cell surface receptor immunoglobulin-like fold (TIG), RNA recognition motif (RRM), KH, and acyl-CoA oxidase (ACOX) domain.

(665 KB JPG)

Figure S4

Ataxin-3 Modifier Genes Mitigate Toxicity of PolyQ Protein in the Nervous System:

(A) Animals expressing SCA3trQ78 in the nervous system do not develop to adults, with lethality of larvae and pupae that fail to form completely (pupa shown).

(B) With co-expression of EP1050, now the animals develop to the pharate pupal stage, with eyes, wings, and legs fully formed, though the animals fail to emerge from the pupal case. Genotypes: (A) elav-GAL4; UAS-SCA3trQ78(S)/+ and (B) elav-GAL4; UAS-SCA3trQ78(S)/EP1050.

(C) Table of lethality with or without added select modifier genes. *, Lethality assessed with neuronal expression by the elav-GAL4 driver, which is expressed in all neurons through development and in the adult.

(901 KB JPG)

Figure S5

Genomic Organization of dpld:

(A) Genomic organization of dpld with insertion sites of EP alleles indicated. The A form of the dpld transcript is shown (three splice variants are predicted), black represents exons, and blue indicates the 5′ UTR and 3′ UTR. EP insertions are in the same orientation as gene expression. dpld is on 2R, cytological position 43C5. The centromere is to the right. Restriction enzyme sites are: X, XbaI; H, HindIII; R, EcoRI; B, BamHI; S, SacII; P, PstI.

(B) Schematic representation of Dpld protein and select homologs (Dm Brat, Ce Lin-41, and Homo sapiens Lin-41). Blue is the B-box zinc finger, yellow is the coiled-coil, red is NHL repeats, and pink is a ring finger domain. The percent identity of the NHL domain to that of Dpld is noted.

(C) NHL domain based evolutionary tree showing relatedness of Dpld to that of other RBCC-NHL family members in nematode, fly, and human. Dpld is most homologous to Lin-41; the other studied fly NHL protein Brat is distantly related.

(D) Sequence alignment of the B1 and B2 boxes, and the NHL domain of Dpld to those of Brat, human Lin-41, and C. elegans Lin-41. Amino acid identities in black; similarities and identities in three of the four sequences are in gray. The cysteine and histidine residues that define the B-box subclass of Zn finger are marked with an asterisk (*). The positions of NHL repeats are noted.

(806 KB JPG)

Figure S6

Dpld Suppresses Ataxin-3-Associated Neurodegeneration:

External eye and internal retinal sections of 1-d flies.

(A) Control fly bearing only the driver line. Genotype w; gmr-GAL4/+.

(B) Ataxin-3 induces severe retinal degeneration. Genotype w; gmr-GAL4 UAS-SCA3trQ78/+.

(C) Co-expression of dpldJM265 with SCA3trQ78 results in normal pigmentation and improved retinal structure. Genotype w; gmr-GAL4 UAS-SCA3trQ78/dpldJM265.

(D) Expression of dpld from a UAS-dpld transgene improves retinal structure, indicating that suppression of polyQ toxicity is due to increased Dpld activity. Genotype w; gmr-GAL4 UAS-SCA3trQ78 /+; UAS-dpld J990-P2/+.

(E–G) Tangential retinal sections of fly expressing SCA3trQ78 alone or with Dpld. Flies expressing SCA3trQ78 have a normal retina (E) at 1 d, which undergoes severe progressive degeneration by (F) 21 d. Genotype w; UAS-SCA3trQ78/+; rh1-GAL4/+.

(G) Flies with SCA3trQ78 and UAS-dpldJ990-P2 are normal. Genotype UAS-SCA3trQ78/+; rh1-GAL4 /UAS-dpld.

(H) Rhabdomere counts in individual ommatidia by optical neutralized corneal pseudopupil (see reference contained in Text S1). Flies expressing SCA3trQ78 show degeneration in the number of rhabdomeres per ommatidial unit at 21 d. Flies expressing SCA3trQ78 and dpldJ990-P2 retain rhabdomere numbers over 21 d; dpldJM265 has partial rescue compared to controls.

(1.5 MB JPG)

Figure S7

Select Modifiers More Effectively Mitigate Toxicity of Full Length Ataxin-3:

(A) Expression of full-length SCA3Q84 causes a mild eye degeneration. Genotype w; gmr-GAL4 UAS-SCA3Q84 /+.

(B–C) The modifiers (B) CG14207EP1348 and (C) polyubiquitin CR11700EP1384 suppress full-length disease toxicity stronger than they do the truncated disease protein. Genotypes w; gmr-GAL4 UAS-SCA3Q84 in trans to EP1348 and EP1384.

(482 KB JPG)

Figure S8

Additional Details of Dpld and Hsc70C:

(A–C) Horizontal eye section of a fly eye expressing dpld-eYFP shows (B) nonhomogenous distribution and localization to membranous structures. (A) Hoechst staining. (C) Overlay shows that Dpld does not localize to nucleus but is concentrated around it. Genotype w; UAS-dpld-eYFP in trans to gmr-GAL4.

(D–F) Horizontal retinal section showing Dpld localization in the presence of SCA3trQ78. (D) eYFP staining for Dpld and (E) HA staining for SCA3trQ78. (F) Overlay shows that Dpld is not recruited to the SCA3trQ78 aggregates. Genotype w; gmr-GAL4 UAS-SCA3trQ78 in trans to UAS-dpld-eYFP.

(G and H) GFP insertion allele of Hsc70Cb enhances Ataxin-3 neurotoxicity. Hsc70CbGFP fusion protein was confirmed by Western immunoblot (unpublished data). The line is homozygous lethal indicating a potential loss of function of allele of Hsc70Cb. Genotypes w; gmr-GAL4 UAS-SCA3trQ78/+ (H) and w; gmr-GAL4 UAS-SCA3trQ78/+; Hsc70CbCB02656/+.

(I–K) Hsc70Cb protein trap line strikingly increases Ataxin-3 inclusions in the lamina and medulla, indicating enhanced cytoplasmic disease protein. (I) Hoescht staining for nuclei. Genotypes gmr-GAL4 UAS-SCA3Q84/+ (I and J), w; gmr-GAL4 UAS-SCA3Q84/+; Hsc70CbCB02656/+.

(L–O) Hsc70Cb suppresses (L and M) normal and (N and O) mutant R406W tau-induced degeneration. Genotypes (L) w; gmr-GAL4/+; UAS-tau/+, (N) w; gmr-GAL4/+; UAS-tau/ Hsc70CbCB02656, (M) w; gmr-GAL4/+; UAS-tau.R406W/+, and (N) w; gmr-GAL4/+; UAS-tau.R406W/ Hsc70CbCB02656.

(2.1 MB JPG)

Figure S9

Dpld Modulates Body Size:

(A–F) dpld and brat share a function in growth regulation (see reference contained in Text S1), but the activities of dpld to suppress polyQ toxicity and cell death are special to dpld. The effect of dpld on eye and body size were mitigated by reducing autophagy gene activity (not shown).

(A right, and C) Dpld expression during development reduces body size (A, fly on the right) and (C) eye size, similar to brat over-expression. Genotype in (A) w; act5C-GAL4 in trans to + or UAS-dpld and (C) w; ey-GAL4/UAS-dpld.

(A left, B) Normal fly body and eye size. Genotype (A) w; act5C-GAL4/+ and (B) w; ey-GAL4/+.

(D, E) Directed expression of brat does not mitigate degeneration induced by SCA3trQ78 either (D) externally or (E) internally. Genotype w; gmr-GAL4 UAS-SCA3trQ78 in trans to UAS-brat.

(F) Brat does not mitigate hid-induced programmed cell death. Genotype w; gmr-hid gmr-GAL4 in trans to UAS-brat.

(769 KB JPG)

Table S1

Summary of Genetic Modifiers of Ataxin-3:

The location and orientation of the EP insertions are indicated, including the method used to confirm that the insertions caused overexpression of the targeted gene. Note that insertions into novel genes were reverted to confirm that the EP insertion was causal in modification.

(98 KB DOC)

Table S2

Loss-of-Function Deficiency Regions and Alleles of Modifiers of Ataxin-3 Neurodegeneration That Were Tested:

Alleles and deficiency lines of Ataxin-3 modifiers were tested for modulation of polyQ toxicity. See also Figure 1K–1O.

(89 KB DOC)

Table S3

Protein Interactions of Ataxin-3 Genetic Modifiers:

List of human orthologues of the fly modifiers found. The degree of interaction from Ataxin-3 is from Table 5 of Lim et al. (see reference contained in Text S1). Degree of interaction is based on the distance each orthologue is from the seven primary interactors defined for Ataxin-3 (ARHGAP19, EWSR1, LIN10, RAD23A, RAD23B, TEX11, and PRKCABP) (see reference contained in Text S1) and VCP/TER94 (see reference contained in Text S1).

(122 KB DOC)

Text S1

Supplemental Methods:

(62 KB DOC)

Acknowledgments

We thank R. Pittman and D. Lessing for critical comments. We thank J.M. Belote, C. Desplan, M. Feany, T. Neufeld, H. Steller, R. Wharton, M. Buszczak, H. Zoghbi, and S. Lindquist, and the Bloomington Stock Center and Developmental Studies Hybridoma Bank (funding from NICHD) for fly lines, reagents, or advice. We thank R. Bernstein, A. Bovell, L. Faust, L. Morabito, and X. Teng for outstanding technical assistance.

Abbreviations

GFP
green fluorescent protein
NI
nuclear inclusion
polyQ
polyglutamine
SCA3
spinocerebellar ataxia type-3
UPS
ubiquitin-proteasomal system

Footnotes

¤ Current address: Howard Hughes Medical Institute, Janelia Farm Research Campus, Ashburn Virginia, United States of America

Author contributions. JB and NMB conceived and designed the experiments, performed the experiments, analyzed the data, and wrote the paper.

Funding. This work was funded by the National Institute of Neurological Disorders and Stroke and the Packard Foundation (to NMB). NMB is an investigator of the Howard Hughes Medical Institute.

Competing interests. The authors have declared that no competing interests exist.

References

  • Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci. 2000;23:217–247. [PubMed]
  • Gusella JF, MacDonald ME. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci. 2000;1:109–115. [PubMed]
  • Ikeda H, Yamaguchi M, Sugai S, Aze Y, Narumiya S, et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet. 1996;13:196–202. [PubMed]
  • Perutz MF. Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem Sci. 1999;24:58–63. [PubMed]
  • Kim S, Nollen EA, Kitagawa K, Bindokas VP, Morimoto RI. Polyglutamine protein aggregates are dynamic. Nat Cell Biol. 2002;4:826–831. [PubMed]
  • Cummings CJ, Mancini MA, Antalffy B, DeFranco DB, Orr HT, et al. Chaperone suppression of aggregation and altered subcellular proteasome localization imply protein misfolding in SCA1. Nat Genet. 1998;19:148–154. [PubMed]
  • Lansbury PT, Lashuel HA. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature. 2006;443:774–779. [PubMed]
  • Lee VM, Trojanowski JQ. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery. Neuron. 2006;52:33–38. [PubMed]
  • Aguzzi A, Heikenwalder M. Pathogenesis of prion diseases: current status and future outlook. Nat Rev Microbiol. 2006;4:765–775. [PubMed]
  • Marsh JL, Thompson LM. Drosophila in the study of neurodegenerative disease. Neuron. 2006;52:169–178. [PubMed]
  • Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet. 2005;39:153–171. [PubMed]
  • Driscoll M, Gerstbrein B. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet. 2003;4:181–194. [PubMed]
  • Outeiro TF, Muchowski PJ. Molecular genetics approaches in yeast to study amyloid diseases. J Mol Neurosci. 2004;23:49–60. [PubMed]
  • Warrick JM, Paulson HL, Gray-Board GL, Bui QT, Fischbeck KH, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell. 1998;93:939–949. [PubMed]
  • Warrick JM, Morabito LM, Bilen J, Gordesky-Gold B, Faust LZ, et al. Ataxin-3 suppresses polyglutamine neurodegeneration in Drosophila by a ubiquitin-associated mechanism. Mol Cell. 2005;18:37–48. [PubMed]
  • Chan HY, Warrick JM, Gray-Board GL, Paulson HL, Bonini NM. Mechanisms of chaperone suppression of polyglutamine disease: selectivity, synergy and modulation of protein solubility in Drosophila. Hum Mol Genet. 2000;9:2811–2820. [PubMed]
  • Morley JF, Brignull HR, Weyers JJ, Morimoto RI. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2002;99:10417–10422. [PMC free article] [PubMed]
  • Kazemi-Esfarjani P, Benzer S. Genetic suppression of polyglutamine toxicity in Drosophila. Science. 2000;287:1837–1840. [PubMed]
  • Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et al. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature. 2000;408:101–106. [PubMed]
  • Nollen EA, Garcia SM, van Haaften G, Kim S, Chavez A, et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc Natl Acad Sci U S A. 2004;101:6403–6408. [PMC free article] [PubMed]
  • Willingham S, Outeiro TF, DeVit MJ, Lindquist SL, Muchowski PJ. Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science. 2003;302:1769–1772. [PubMed]
  • Bilen J, Liu N, Burnett BG, Pittman RN, Bonini NM. MicroRNA pathways modulate polyglutamine-induced neurodegeneration. Mol Cell. 2006;24:157–163. [PubMed]
  • Doss-Pepe EW, Stenroos ES, Johnson WG, Madura K. Ataxin-3 interactions with rad23 and valosin-containing protein and its associations with ubiquitin chains and the proteasome are consistent with a role in ubiquitin-mediated proteolysis. Mol Cell Biol. 2003;23:6469–6483. [PMC free article] [PubMed]
  • Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Hum Mol Genet. 2003;12:3195–3205. [PubMed]
  • Donaldson KM, Li W, Ching KA, Batalov S, Tsai CC, et al. Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine aggregates. Proc Natl Acad Sci U S A. 2003;100:8892–8897. [PMC free article] [PubMed]
  • Chow MK, Mackay JP, Whisstock JC, Scanlon MJ, Bottomley SP. Structural and functional analysis of the Josephin domain of the polyglutamine protein ataxin-3. Biochem Biophys Res Commun. 2004;322:387–394. [PubMed]
  • Rorth P. A modular misexpression screen in Drosophila detecting tissue-specific phenotypes. Proc Natl Acad Sci U S A. 1996;93:12418–12422. [PMC free article] [PubMed]
  • Wellington CL, Ellerby LM, Hackam AS, Margolis RL, Trifiro MA, et al. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J Biol Chem. 1998;273:9158–9167. [PubMed]
  • Berke SJ, Schmied FA, Brunt ER, Ellerby LM, Paulson HL. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3. J Neurochem. 2004;89:908–918. [PubMed]
  • Mauri PL, Riva M, Ambu D, De Palma A, Secundo F, et al. Ataxin-3 is subject to autolytic cleavage. FEBS J. 2006;273:4277–4286. [PubMed]
  • Warrick JM, Chan HY, Gray-Board GL, Chai Y, Paulson HL, et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70. Nat Genet. 1999;23:425–428. [PubMed]
  • Bonini NM. Chaperoning brain degeneration. Proc Natl Acad Sci U S A 99 Suppl. 2002;4:16407–16411. [PMC free article] [PubMed]
  • Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature. 2004;431:805–810. [PubMed]
  • Ross CA, Pickart CM. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases. Trends Cell Biol. 2004;14:703–711. [PubMed]
  • Saville KJ, Belote JM. Identification of an essential gene, l(3)73Ai, with a dominant temperature-sensitive lethal allele, encoding a Drosophila proteasome subunit. Proc Natl Acad Sci U S A. 1993;90:8842–8846. [PMC free article] [PubMed]
  • Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet. 2004;36:585–595. [PubMed]
  • Baehrecke EH. Autophagy: dual roles in life and death? Nat Rev Mol Cell Biol. 2005;6:505–510. [PubMed]
  • Scott RC, Schuldiner O, Neufeld TP. Role and regulation of starvation-induced autophagy in the Drosophila fat body. Dev Cell. 2004;7:167–178. [PubMed]
  • Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159. [PubMed]
  • Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509–519. [PubMed]
  • Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711–714. [PubMed]
  • Satyal SH, Schmidt E, Kitagawa K, Sondheimer N, Lindquist S, et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 2000;97:5750–5755. [PMC free article] [PubMed]
  • Gidalevitz T, Ben-Zvi A, Ho KH, Brignull HR, Morimoto RI. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science. 2006;311:1471–1474. [PubMed]
  • Brooks E, Arrasate M, Cheung K, Finkbeiner SM. Using antibodies to analyze polyglutamine stretches. Methods Mol Biol. 2004;277:103–128. [PubMed]
  • Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science. 2003;300:486–489. [PubMed]
  • Rubinsztein DC. The role of intracellular protein degradation pathways in neurodegeneration. Nature. 2006;443:780–786. [PubMed]
  • Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science. 2001;292:1552–1555. [PubMed]
  • Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science. 2004;305:1292–1295. [PubMed]
  • Bennett EJ, Bence NF, Jayakumar R, Kopito RR. Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation. Mol Cell. 2005;17:351–365. [PubMed]
  • Komatsu M, Waguri S, Chiba T, Murata S, Iwata J, et al. Loss of autophagy in the central nervous system causes neurodegeneration in mice. Nature. 2006;441:880–884. [PubMed]
  • Hara T, Nakamura K, Matsui M, Yamamoto A, Nakahara Y, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature. 2006;441:885–889. [PubMed]
  • Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron. 2003;40:25–40. [PubMed]
  • Bilen J, Liu N, Bonini NM. A new role for microRNA pathways: modulation of degeneration induced by pathogenic human disease proteins. Cell Cycle. 2006;5:2835–2838. [PubMed]
  • Schaefer A, O'Carroll D, Tan CL, Hillman D, Sugimori M, et al. Cerebellar neurodegeneration in the absence of microRNAs. J Exp Med. 2007;204:1553–1558. [PMC free article] [PubMed]
  • Lim J, Hao T, Shaw C, Patel AJ, Szabo G, et al. A protein-protein interaction network for human inherited ataxias and disorders of Purkinje cell degeneration. Cell. 2006;125:801–814. [PubMed]
  • Boeddrich A, Gaumer S, Haacke A, Tzvetkov N, Albrecht M, et al. An arginine/lysine-rich motif is crucial for VCP/p97-mediated modulation of ataxin-3 fibrillogenesis. EMBO J. 2006;25:1547–1558. [PMC free article] [PubMed]
  • Goedert M, Spillantini M. A century of Alzheimer's disease. Science. 2006;314:777–781. [PubMed]
  • Shulman JM, Feany MB. Genetic modifiers of tauopathy in Drosophila. Genetics. 2003;165:1233–1242. [PMC free article] [PubMed]
  • Richter-Landsberg C, Bauer NG. Tau-inclusion body formation in oligodendroglia: the role of stress proteins and proteasome inhibition. Int J Dev Neurosci. 2004;22:443–451. [PubMed]
  • Kraemer BC, Burgess JK, Chen JH, Thomas JH, Schellenberg GD. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum Mol Genet. 2006;15:1483–1496. [PubMed]
  • Roth P, Xylourgidis N, Sabri N, Uv A, Fornerod M, et al. The Drosophila nucleoporin DNup88 localizes DNup214 and CRM1 on the nuclear envelope and attenuates NES-mediated nuclear export. J Cell Biol. 2003;163:701–706. [PMC free article] [PubMed]
  • Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401–415. [PubMed]
  • Velazquez JM, Lindquist S. Hsp70: nuclear concentration during environmental stress and cytoplasmic storage during recovery. Cell. 1984;36:655–662. [PubMed]

Articles from PLoS Genetics are provided here courtesy of Public Library of Science
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Links